A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 761-767

  Haas, Naomi B ⁱ   Lin, Xinyi ^a   Manola, Judith ^b   Pins, Michael ^c   Liu, Glenn ^d   McDermott, David ^e   Nanus, David ^f   Heath, Elisabeth ^g   Wilding, George ^d   Dutcher, Janice ^h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Doxorubicin; Gemcitabine; Kidney cancer; Renal cell cancer; Sarcomatoid

Indexed keywords

DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COUGHING; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY CARCINOMA; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMATOID CARCINOMA; STOMATITIS; THORAX PAIN; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84866274288     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9829-8     Document Type: Article

References (29)

1. Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer. 2001; 91(2):354-61.
2. Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090-5.
3. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-91.
4. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27(5):612-24.
5. Ficarra V, Prayer-Galetti T, Novella G, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol. 2003;43:663-9.
6. Patard JJ, Leray E, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763-71.
7. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid Renal Cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435-41.
8. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:64-275.
9. Jones TD, Eble JN, Wang M, et al. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer. 2005;104:1195-203.
10. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1 alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177: 1258-63.
11. Bangalore N, Bhargava P, Hawkins MJ, et al. Sustained response of sarcomatoid renal cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol. 2001;12: 271-4.
12. Hoshi S, Satoh M, Ohyama C, Hiramatu M, et al. Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol. 2003;8(2):113-7.
13. Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma: a treatable entity. Cancer. 1987;60:1313-8.
14. Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168(3):959-61.
15. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101(7):1545-51.
16. Dutcher JP, Nanus D. Long term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2010;Aug 18 (epub ahead of print).
17. Eble JN. Renal cell carcinoma, unclassified, pg 43. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization Classification of Tumours, Pathology and Genetics. Tumors of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
18. Langner C, von Wasielewski R, Ratschek M, et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004;445(6):631-6.
19. Ishizaki H, Yano H, Tsuneoka M, et al. Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol Int. 2007;57(10):672-80.
20. Visapää H, Seligson D, Huang Y, et al. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003;30(6): 387-9.
21. Mertz KD, Demichelis F, Kim R, et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol. 2007;38(10): 1454-62.
22. Tamboli P, Prieto VG, Bekele BN, et al. The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol 2003;22:408a (abstr 1641).
23. Ku JH, Park YH, Myung JK, Moon KC, Kwak C, Kim HH. Expression of hypoxia inducible factor-1alpha and 2alpha in conventional renal cell carcinoma with or without sarcomatoid differentiation. Urol Oncol. 2009;Nov 12.
24. Golshayan AR, George S, Heng DY, Elson P, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235-41.
25. Vogelzang NJ, Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol. 2010;Oct 25.
26. Haas NB. Paired specimens: an opportunity to answer some important questions. Cancer. 2010;116(3):574-6.
27. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006; 12(1):144-51.
28. Michaelson M, Schwarzberg A, Ryan D, et al. A phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. 2008 ASCO Genitourinary Cancers Symposium 362.
29. Pandya SS, Mier JW, Cho D, McDermott D. The Role of adding gemcitabine at time of sunitinib resistance in patients with metastatic RCC. 2008 ASCO Genitourinary Cancers Symposium 380.